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TRIB2 confers resistance to anti-cancer therapy by
activating the serine/threonine protein kinase AKT
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Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment
failure for many cancer patients. The identiﬁcation of molecular mechanisms involved in drug
resistance or sensitization is imperative. Here we report that tribbles homologue 2 (TRIB2)
ablates forkhead box O activation and disrupts the p53/MDM2 regulatory axis, conferring
resistance to various chemotherapeutics. TRIB2 suppression is exerted via direct interaction
with AKT a key signalling protein in cell proliferation, survival and metabolism pathways.
Ectopic or intrinsic high expression of TRIB2 induces drug resistance by promoting phospho-
AKT (at Ser473) via its COP1 domain. TRIB2 expression is signiﬁcantly increased in tumour
tissues from patients correlating with an increased phosphorylation of AKT, FOXO3a, MDM2
and an impaired therapeutic response. This culminates in an extremely poor clinical outcome.
Our study reveals a novel regulatory mechanism underlying drug resistance and suggests that
TRIB2 functions as a regulatory component of the PI3K network, activating AKT in cancer
cells.
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T
he emergence of drug-resistant tumour cells is a major
obstacle for both conventional chemotherapeutics
as well as novel targeted therapeutics1. As FOXO
proteins play a key role in the action of several anticancer
drugs, proteins that are capable of suppressing FOXO activity
are strong candidates to confer drug resistance2–7. Our previous
large scale genetic screen identiﬁed the kinase-like protein
Tribbles 2 (TRIB2) as a FOXO suppressor protein8, while
TRIB2 has also been implicated in the development and
progression of melanoma and leukaemia8–11.
In our study presented here, we describe a new regulatory
mechanism underlying drug resistance in different cancer entities
and suggests that TRIB2 functions as a critical regulatory
component of the PI3K signalling network, activating AKT in
cancer cells. In addition, our data support the use of TRIB2
as a biomarker for both prognosis and personalized cancer
therapy, as well as identifying this protein as a molecular target
for combination cancer treatment.
Results
TRIB2-conferred resistance to anti-cancer therapeutics. To test
our hypothesis that the TRIB2 protein confers resistance to
anti-cancer drugs, we ﬁrst generated and then examined the
sensitivity of several stable, isogenic TRIB2 in vitro models
(Supplementary Table 1; Supplementary Fig. 1) after treatment
with the dual PI3K/mTOR kinase inhibitor BEZ235. High-TRIB2
expression signiﬁcantly increased cell resistance to BEZ235
treatment characterized by a signiﬁcantly lower sub-G1
cell population and a reduction of caspase-3 cleavage (Fig. 1a,b).
To characterize the proﬁle of kinases that were affected by
TRIB2 status, we tested a range of inhibitors that display
distinct kinase selectivity (summarized in Fig. 1c). TRIB2
protein expression signiﬁcantly inﬂuenced isogenic cell line
sensitivity to BAY236 (BAY 80-6946) and BAY1082439 treatment
(Fig. 1d). This response was independent of the cell cycle
(Supplementary Fig. 2a–c), indicating that TRIB2 reduces cell
death induced by PI3K inhibitors and thus is capable of con-
ferring resistance to these drugs. Strikingly, isogenic cell line
sensitivity to inhibition of the central effector protein AKT (ref.
12) and to the mTORC1/2 inhibitor TORIN1 was independent of
TRIB2 status (Fig. 1e). We investigated this further and exposed
our isogenic cell lines to rapamycin, a speciﬁc mTORC1 inhibitor.
Noticeably, TRIB2 status correlated with resistance to this com-
pound (Fig. 1f). Taken together our data raises the intriguing
possibility that TRIB2 acts upstream of these proteins affecting
AKT and mTORC2.
TRIB2 protein level correlates with AKT activation. To inves-
tigate this further, we performed western blot analyses before
and after clinically representative drug treatment with each
compound using our isogenic cell lines. We note a prominent
TRIB2-dependent disparity in the levels of pSer473-AKT1
and total AKT using our in vitro models. In melanoma
and osteosarcoma cells with high-TRIB2 protein expression,
we identiﬁed signiﬁcantly higher levels of total AKT and pSer473-
AKT and the opposite was observed in cancer cells with TRIB2
depletion (Fig. 2a). Consistent with our previous data, this was
not observed for pThr308-AKT1, where there were readily
detectable levels of this AKT isoform independent of TRIB2
status in each in vitro model. These data support the intriguing
possibility that TRIB2 might promote the further activation of
AKT via Ser473 phosphorylation in a PI3K and mTORC1 inde-
pendent manner. In this way, drugs targeting these proteins
within the PI3K pathway are not effective in tumours where
TRIB2 expression is up-regulated. To investigate this possibility,
we analysed signalling components within the PI3K/AKT net-
work and found that TRIB2 over expression increased the acti-
vation of pSer473-AKT before and in the presence of PI3K and
mTOR inhibitors (Fig. 2b). Importantly, while TRIB2 protein
over expression signiﬁcantly increased pSer473-AKT1 levels,
isogenic cell line exposure to our inhibitor compounds reduced
the level of pSer473-AKT, indicating that the upstream compo-
nents of this network remain functional within these in vitro
models. To support this, we transiently transfected wildtype
AKT, a phospho-mimetic AKT (AKTSer473D), wildtype
FOXO3a or a phosphor-mutant FOXO3a (FOXO3a-AAA) into
our isogenic cell lines (Supplementary Fig. 3a,b). We note that
the over-expression of either AKTSer473D or FOXO3a-AAA
negated the TRIB2-dependent resistance to BEZ235 treatment.
In contrast, over-expression of either WT AKT or FOXO3a did
not. For this we conclude that TRIB2-mediated resistance
was AKT-dependent via FOXO3a. Interestingly there was no
signiﬁcant difference in protein expression for PDK1, pSer241-
PDK1, RAPTOR, pSer792-RAPTOR, p70S6K and only a slightly
increased level of pThr389-p70S6K correlated with TRIB2
expression (Supplementary Fig. 4) Taken together we conclude
that TRIB2-conferred resistance to PI3K and mTORC1 inhibitors
is independent of PDK1 and p70S6K.
TRIB2 and AKT interact and form a protein-protein complex.
FOXOs have been shown to be the major transcriptional effectors
following PI3K inhibition13 and consistent with this ﬁnding, we
observe signiﬁcantly elevated pSer235-FOXO3a protein levels and
a concomitant suppression of FOXO-dependent gene expression
in cells with high-TRIB2 protein expression (Fig. 2c,d). Our
data raise the hypothesis that TRIB2-dependent FOXO
suppression is indirect and rather, could be mediated via p473-
AKT1 activation. To address this hypothesis we investigated the
mTORC2/AKT/FOXO3a cascade as mTORC2 is responsible for
the phosphorylation of ser473 within AKT1 (ref. 14). We
questioned if there was physical interaction between TRIB2,
AKT1 and pThr1135-RICTOR using co-immunoprecipitation
and protein fragment complementation assays15–17. The results
showed a strong interaction between TRIB2 and AKT1 but could
not observe TRIB2/RICTOR binding (Fig. 2e,f). Strikingly, the
TRIB2/AKT1 complex (including the intensity of the interaction)
was as strong as the known AKT1/JIP1 interaction18. Developing
these ﬁndings further, we addressed the functional importance of
FOXO and RICTOR in TRIB2-dependent drug resistance. Four
different shRNA constructs were used to stably silence FOXO3a
expression (Supplementary Fig. 5). The depletion of FOXO3a
expression signiﬁcantly increased in vitro resistance to PI3K
inhibitors regardless of TRIB2 status (Fig. 3a). Furthermore,
FOXO3a depletion abolished the TRIB2-dependent difference, we
previously observed for FOXO-regulated gene transcription in
our isogenic cell lines (Fig. 3b). In addition to phosphorylating
and directing FOXO3a for proteasome mediated degradation,
AKT1 can also suppress apoptosis by activating the E3 ubiquitin
ligase mouse double minute 2 homologue (MDM2), thus
inhibiting p53-mediated apoptosis6,19. To analyse the role of
TRIB2 within this ‘arm’ of the AKT network, we broadened our
study to include ﬁrst line chemotherapeutics known to act
through p53 that are independent of FOXO (Fig. 3c,
Supplementary Fig. 6). Remarkably, TRIB2 over expression
signiﬁcantly increased cell resistance to dacarbazine (DTIC),
gemcitabine and 5-ﬂuorouracil (5-FU) induced cell death
independent of FOXO. Accordingly, high-TRIB2 expression
was associated with notably elevated pSer166-MDM2 protein
levels (Fig. 3d). Therefore, we questioned whether p53 regulation
was disrupted by increased TRIB2 protein levels. We found that
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high-TRIB2 protein expression correlated with a signiﬁcantly
lower p53 protein level in the absence of DNA damage or cellular
stress consistent with increased MDM2 activity (Fig. 3d).
Concomitant to this reduced p53 protein level, we observed the
diminished expression of p53 target genes including p21, MDM2,
Bax and PUMA (Fig. 3e). Altogether these data highlight the
involvement of TRIB2 within the PI3K signalling network,
affecting cell line resistance to various anti-cancer agents by
activating AKT1, inhibiting FOXO and p53.
It has been previously reported that TRIB2 associated with and
inhibited the transcription factor CCAAT/enhancer-binding
protein alpha (C/EBPa)11. Gene expression analysis in our
isogenic cell lines revealed that high-TRIB2 expression leads to
reduced number of C/EBPa transcripts and the downregulation of
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Figure 1 | Overexpression of TRIB2 confers in vitro resistance to PI3K inhibitors. (a) Matched isogenic TRIB2 cell line FACS analysis following exposure
to BEZ235 (n¼ 6), sc.shRNA indicates scramble shRNA while TRIB2 shRNA indicates stable shRNA knockdown for TRIB2 in each cell lines. P values are
indicated for each comparison by two-way analysis of variance (ANOVA) and data represent the mean±s.d. (b) (left) Higher pro-caspase3 and reduced
cleavage of caspase3 in TRIB2 overexpressing cells after treatment with BEZ235, (50mg total protein loaded per lane and separated by 10% SDS–PAGE).
(right) Densitometry for cleaved caspase3 and TRIB2 under each condition. Data normalized to actin and analysed in ImageJ. Data indicates relative mean
intensity±s.e.m and analysed by two-way ANOVA. (c) Schematic showing the target speciﬁcity for each compound, the inhibitory concentration
50% (IC50) and commercial name. (d) FACS analysis of TRIB2 isogenic cell lines 72 h post exposure to various pre-clinical PI3K inhibitors (n¼6).
(e) Isogenic TRIB2 cell line FACS analysis 72 h post-AKT, mTOR1/2 or mTOR1 inhibition (n¼ 6). P values are indicated for each comparison by two-way
analysis of variance (ANOVA) and data represent the mean±s.d.
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C/EBPa target genes (Supplementary Table 5), which might
contribute to the response to drug treatment.
The COP1 domain of TRIB2 is required for AKT activation.
To identify directly the TRIB2 functional domains that effect
AKT activation, FOXO3a suppression and confer resistance to
PI3K inhibitors, we employed a variety of mutated TRIB2
proteins (Supplementary Fig. 7a)20. The DC, kinase domain (KD),
DCOP1 and the N-terminal TRIB2 constructs did not confer
resistance to any of the PI3K inhibitors tested (Fig. 3g). However,
the full length, DN and the C-terminal constructs did confer
resistance to each of the investigated therapeutics indicating
that the COP1 region could be driving cell line resistance. In DC,
KD, DCOP1 and N-terminal transfected cells, we observe little to
no change in the level of pSer473-AKT1. In contrast, in untreated
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cells transfected with full length, DN or the C-terminal TRIB2
constructs, the levels of pSer473-AKT1, pSer253-FOXO3a and
pSer166-MDM2 increased signiﬁcantly (Fig. 3h). Alongside, these
phosphorylation events we observed a signiﬁcant reduction of
FOXO3a-dependent gene and protein expression (Supplementary
Fig. 7b,c). Taken together, these data support that the TRIB2
COP1 domain promotes AKT activation repressing FOXO3a and
p53 activity, thereby fuelling cellular resistance to PI3K inhibitor
regimes.
TRIB2 protein confers in vivo resistance to BEZ235 treatment.
To address if TRIB2 over expression ablated tumour regression
following the in vivo administration of PI3K inhibitors, we
established isogenic 293T subcutaneous tumours in the ﬂanks of
NOD/Scid mice. Tumours formed equivalently in these mice
irrespective of TRIB2 status. The daily oral administration of
BEZ235 resulted in the regression of 293T-GFP xenograft
tumours and a statistically signiﬁcant increase in survival. In
contrast, 293T-TRIB2 tumours were highly resistant to treatment,
correlating with our in vitro studies indicating that TRIB2 over
expression signiﬁcantly reduced the effectiveness of BEZ235
treatment in vivo (Fig. 4a,b). To further support our in vitro
analysis, we also collected (where possible) tumours from each
mouse and evaluated the protein expression proﬁles (Fig. 4c). We
note that while there was variable overall protein expression
within the various treatment groups, that 293T-TRIB2 BEZ235
treated tumours had signiﬁcantly higher total and pSer473 AKT
compared to 293T-GFP BEZ235 treated tumours. In contrast
293T-TRIB2 BEZ235 treated tumours show attenuated FasLG
protein expression.
TRIB2 status corresponds to clinical outcome. We next
questioned if these ﬁndings are representative of the clinical
situation. We collected tumour tissue samples from patients
with melanoma, pancreatic and colon cancer prior to standard
anti-cancer therapies (DTIC, gemcitabine or paclitaxel).
Compared to normal tissue samples, TRIB2 transcription
and TRIB2 protein expression was signiﬁcantly increased in
metastatic melanoma, primary colon and primary pancreatic
cancer tissue samples (Fig. 4d–f; Supplementary Fig. 8). We did
not detect a signiﬁcant increase in either TRIB1 or TRIB3
expression in any of the samples analysed (Supplementary Fig. 9).
Concomitant with TRIB2 status, we found that pSer473-AKT1
and pSer253-FOXO3a protein levels were signiﬁcantly higher,
while the transcript and protein levels of the FOXO-dependent
genes BIM, FasLG and TRAIL were signiﬁcantly lower in ex vivo
melanoma samples compared to normal control tissue samples.
Importantly, when we classiﬁed our samples based on the clinical
outcome of the respective patients, we noted that TRIB2
expression correlated with a signiﬁcantly worse prognosis
(Fig. 4d). We next investigated whether our transcription data
correlated with protein levels. First, TRIB2 protein expression was
distinctly increased in melanoma tissue samples compared to
normal skin and second, the highest TRIB2 protein expression
was observed in melanoma tissues samples from patients with
a poor clinical outcome (Fig. 4e; Supplementary Fig. 10). We next
questioned whether there was also a de-regulated AKT signalling
within our clinical samples. Consistent with both our in vitro
and in vivo data, we observed signiﬁcantly elevated total
AKT, pSer473-AKT1, pSer253-FOXO3a and pSer166-MDM2
and no signiﬁcant difference regarding pThr308-AKT1. Our
study also demonstrated that pSer473-AKT1 and pSer253-
FOXO3a levels correlated with melanoma patient prognosis.
Further examination of AKT in our clinical samples revealed that
TRIB2 and pSer473-AKT1 co-localize in melanoma cells from
patients with progressive disease (Fig. 4f). Finally, we examined
the clinical signiﬁcance of our ex vivo data within large patient
cohorts. Melanoma, colon and pancreatic tumour tissue samples
were analysed based on TRIB2 expression (low Z1.5, high Z2.5
versus normal tissue expression) and Kaplan–Meier survival
curves plotted. For melanoma and colon cancer patients, high-
TRIB2 expression correlated with a signiﬁcantly worse clinical
outcome (Fig. 4g,h; Supplementary Fig. 11). For pancreatic
cancer, there was only a strong trend for high-TRIB2 expression,
primarily due to the extremely poor overall prognosis exhibited in
pancreatic cancer patients. We further analysed the GSE65904
data set21 addressing several clinical parameters, which when
combined with TRIB2 expression were used to determine
if TRIB2 expression was dependent or independent of these
prognostic parameters. Using a multivariate cox regression model
we note that TRIB2 transcription is a prognostic factor,
independent of disease stage, tissue involvement, age and
gender (Supplementary Tables 6 and 7). Furthermore, survival
data from the GSE65904 dataset revealed a highly signiﬁcant
TRIB2-dependent distant metastasis-free survival time or disease-
speciﬁc survival time response (Fig. 4g,h). Interestingly, this
correlation to patient prognosis was only observed for TRIB2 and
not for TRIB1 or TRIB3 (Supplementary Fig. 12a–f).
Discussion
Overall, our data reveal novel and important mechanisms
of TRIB2-dependent intrinsic resistance to standard chemo
therapies and PI3K inhibitors. A patient tumour population
with a high-TRIB2 protein level prior to treatment would be
predicted to respond poorly to these treatments by promoting
PI3K/PDK1-independent AKT activation (Fig. 4i). This
Figure 2 | TRIB2 protein expression correlates with AKT activation status and response to PI3K inhibition. (a) TRIB2 protein levels correlate with
AKT-Ser473 phosphorylation in a broad range of model in vitro models. Representative images showing 100mg (TRIB2), 50mg (AKT-Ser473) total protein
loaded per lane separated by 10% SDS–PAGE. sc indicates scramble shRNA within the indicated cell lines. (b) Immunoblot proﬁles for matched isogenic
TRIB2 cell lines for the AKT signalling network. High-TRIB2 expression correlated with signiﬁcantly increased post-translational modiﬁcation(s) of
downstream AKT targets. (c) Temporal inhibition of PI3K-dependent signalling following exposure to PI3K inhibitors. Total protein lysate of
50–200mg was loaded per lane and separated by 6–12% SDS–PAGE. (d) FOXO3a-dependent gene expression was evaluated following 12 h treatment with
PI3K inhibitors. NT indicates no treatment. *Po0.05 **Po0.01, ***Po0.005 by two-way ANOVA. Data represent the±s.d. ns indicates that the
comparison was not statistically signiﬁcant. (e) (left) Co-immunoprecipitation of TRIB2 or total AKT1 from indicated cell lines, (500 mg total protein lysate
immunoprecipitated per lane) and separated by 8–12% SDS–PAGE. (right) Total protein levels in each indicated cell line for co-IP targets (100 mg total
protein loaded per lane and separated by 8–12% SDS–PAGE). (f) Representative yellow ﬂuorescent protein (YFP) complementation microscopy analysis
assay for the assessment of the interaction between AKT1/2 and TRIB2. The leucine zipper Venus1 and Venus2 (ZIPV1-V2) constructs were used
as a positive control, while the combination of TRIB3 V2 and V1 are our negative control. AKT1/2 JIP1 constructs were an additional control of a known
AKTprotein/protein complex. BF indicates bright ﬁeld. (g) (top) Percentage of YFP positive cells determined by FACS. (bottom) Mean ﬂuorescent intensity
of YFP positive cells. One-way ANOVA with Dunnett’s multiple comparison test, n¼4 (*Pr0.05, **Pr0.01, ***Pr0.001). All analysis was conducted
compared to zipV1trib3V2 (lane 1).
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Figure 3 | TRIB2-mediated resistance to chemotherapeutics is via AKT activation, suppressing FOXO3a and p53. (a) Matched isogenic TRIB2 cell line
FACS analysis following the knockdown of FOXO3a and subsequent exposure to BEZ235, BAY236 (copanlisib) or BAY439 (BAY1082439) (n¼6). P values
are indicated for each comparison by two-way ANOVA and data represent the mean±s.d. (b) Quantitative real time PCR (qRT-PCR) analysis of FOXO3a-
dependent gene expression after FOXO3a knockdown and isogenic cell line treatment for 24 h with PI3K inhibitors (n¼ 6), (*Pr0.05, **Pr0.01 and were
analysed by two-way ANOVA). Data represent the mean±s.d. (c) Matched isogenic TRIB2 cell line FACS analysis after 72 h exposure to various
chemotherapeutics (n¼6). P values are indicated for each comparison and data represent the mean±s.d. (d) I Representative immunoblot analysis
showing 50mg (MDM2), 100mg (MDM2-Ser166), 50mg (p53) total protein lysate per lane separated by 6–10% SDS–PAGE. (e) p53-dependent gene
expression was evaluated following TRIB2 isogenic cell line treatment with each indicated chemotherapeutic agent for 24 h. P values are shown for
comparison by 2-way ANOVA (*Pr0.05, **P r0.001, ***P r0.0001) and data shown indicates mean±s.d. (f) Representative immunoblot analysis
showing TRIB2 protein expression (100mg total protein loaded per lane) following exposure to each indicated PI3K inhibitor. (g) FACS analysis of 293Tcells
after transfection of each TRIB2 construct and subsequent exposure to BEZ235, BAY236 (BAY 80-6946) or BAY439 (BAY1082439) (n¼6) for 72 h. P
values are indicated for each comparison by two-way ANOVA and data represent the mean±s.d. P values are shown for each comparison where no
signiﬁcant difference was noted. Data was analysed by 2-way ANOVA *Pr0.05, **Pr0.001. (h) Representative immunoblot analysis showing 50mg
(GFP), 100mg (AKT-Ser473), 100mg (FOXO3a-Ser253), 100mg (MDM2-Ser166) protein expression 48 h post-transfection of the indicated GFP tagged
TRIB2 plasmid constructs.
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AKT activation (and subsequent inactivation of FOXO and p53)
may also be highly relevant for other therapeutics that target
the upstream PI3K/AKT network such as trastuzumab approved
for the treatment of breast and gastric cancers and cetuximab
for the treatment of colon cancer22. Thus, patients whose
tumours display high-TRIB2 expression may not beneﬁt from
speciﬁc PI3K inhibitor therapeutics, rendering TRIB2 as a
suitable biomarker predicting treatment outcome and selecting
patients for individualized therapy. Furthermore, TRIB2
inhibitors might synergize with current therapies targeting the
PI3K/AKT pathway hereby improving treatment outcome and
patient survival.
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Online Content, Any additional Methods, Extended Data
display items and Source Data are available in the online version
of the paper; references unique to these sections appear only in
the online paper.
Methods
Tissue samples. Surgically excised tumour tissue samples from colon cancer
primaries, pancreatic cancer primaries and melanoma metastases were obtained
from patients prior to ﬁrst-line systemic therapy. Core tumour samples of colon
carcinoma were obtained from patients with colon cancer at the time of their
surgery. For each colon cancer patient, a section of matched normal colon
tissue was extracted adjacent to the tumour site. Pancreatic tumour tissue
(and matched normal tissue) was obtained during surgery (employing the Whipple
surgical methodology). Melanoma tumour samples were obtained from metastatic
lesions from patients with advanced melanoma in AJCC stage IV. Informed
consent was obtained for the use of these samples. The samples were freshly frozen
and cryo-preserved until processing. Before analysis, the frozen tissue samples were
split into smaller sections for RNA extraction using TRI-Reagent (Sigma). The
clinical data of the corresponding patients were extracted from the patient ﬁles.
Cell lines and reagents. The human cell lines SK-Mel28, A375, N14, G361,
UACC62, M14 (melanoma), HEK293T (renal cell carcinoma), U2OS [p53þ /þ ],
Soas2 [p53 / ] (osteosarcoma), MCF-7 and MDA-MB231 (breast cancer) were
maintained in DMEM supplemented with 10% FBS (Sigma, PT) and antibiotics
(Gibco, US). Cell lines were mycoplasma tested monthly within the CBMR by
PCR (LookOut Mycoplasma PCR Detection Kit, SIGMA, PT). All cell lines are
indicated in Supplementary Table 1. Antibodies shown in Supplementary Table 2
were used for our immunoblots and signal visualization was achieved using a
ChemidocXRSþ system (BioRad, PT). Dacarbazine (Sigma, PT), gemcitabine
hydrochloride (Eli Lilly #VL7502), AKT inhibitor VIII (Calbiochem, US), BEZ235
(Novartis, US), BAY236, (BAY 80-6946) BAY439 (BAY1082439), BAY1001931
(a gift from Bayer AG, Germany), rapamycin (SIGMA, PT), actinomycin D
(Sigma, PT), and cyclohexamide (Sigma, PT) and MG132 (Sigma, PT) were used
at concentrations described in the text.
Constructs and shRNA. A 3062 bp fragment encoding the entire human Trib2
(hTRIB2) cDNA was sub-cloned into pEGFP-N1 or pIREPuro2 plasmids,
(one co-expressing GFP, the other containing a V5 tag.). Full length human TRIB2
(hTRIB2, 1-343 aa), dN (63-343aa hTRIB2, dC (1-304 aa) hTRIB2, KD (63-304 aa)
hTRIB2, NT (DCT, 1–250 aa) hTRIB2, CT (DNT, 270-343 aa) hTRIB2 and DCOP1
hTRIB2 were kindly provided by W.S. Pear. Each was cloned into pMigR1-myc
plasmid as described in ref. 20. Full length pAKT1-S473D and pCMV6HA-mAKT1
were kindly provided by A. Newton. pECE-Foxo3a-(A)3 and pCLne-wt-Foxo3a
were kindly provided by M. Greenberg. All complementary DNAs (cDNAs) were
sequenced in their entirety to verify there were no mutations in any of our
constructs. FOXO3a shRNA constructs originated from the NKI library, FOXO3a-
826, FOXO3a-827 and FOXO3a-828 were cloned into pRetroSuper. hTRIB2
shRNA-917 or hTRIB2-918 were sub-cloned into pRetroSuper. Each construct was
transfected into indicated cell lines for selection and screening. Full sequences are
provided in our Supplementary Information. For our protein fragment com-
plementation assays, cells were co-transfected with the Venus plasmid constructs23
for AKT1 (1032-2471aa), AKT2 (1032-2477aa) or TRIB2 (1012-2042aa). YFP
signal was quantiﬁed using ﬂow cytometry (FacsCalibur, Becton Dickinson). The
images of the interactions were captured by a Leica DMI 4000B inverted
ﬂuorescence microscope.
Western blot analysis. For the preparation of whole cell lysate, cells were
harvested and lysed using RIPA buffer (50mM Tris–HCl pH 7.4, 1% NP-40,
0.5% Na-deoxychlorate, 150mM NaCl, 1mM EDTA, 2mM NaF, 2mM NaVO4
and 1 protease inhibitor cocktail (PIC) (Sigma). For SDS–polyacrylamide gel
electrophoresis (SDS–PAGE), protein samples were boiled for 5–10min in protein
sample buffer (50mM Tris pH 6.8, 1% SDS, 10% glycerol, 0.01% Bromophenol
Blue, b mercaptoethanol (50 ml per 950 ml sample buffer)). Following electro-
phoresis, proteins were transferred onto nitrocellulose membrane (BioRad).
The membrane was blocked for 1 h at room temperature or overnight at
4 C 5% BSA 0.1% tween20 blocking buffer. Primary antibodies were added
to the membrane (Supplementary Table 2) overnight at 4 C or for 2 h at room
temperature. Secondary antibody was added (Santa Cruz Biotechnology) at
typically 1:5,000 dilution for 1 h at room temperature. Visualization of signal
was achieved using a ChemiDocXRSþ Imaging System (BioRad). Full original
membranes are shown in Supplementary Figs 13–25.
Co-immunoprecipitation. Co-immunoprecipitations (Co-IP) were performed as
described in (ref. 18). Cells were lysed in cold lysis buffer (50mM Tris-Cl at pH 7.4,
150mM NaCl, 1mM EDTA, 1% NP-40, 0.25% sodium deoxycholate, protease
inhibitor mixture). Cell extracts (500 mg) were incubated with the ﬁrst antibodies
(Supplementary Table 2) or control normal IgG on a rotator overnight at 4 C,
followed by addition of protein G magnetic beads (Invitrogen) for 2 h at 4 C.
Beads were then washed four times using the lysis buffer. The immune complexes
were subjected to SDS–PAGE followed by immunoblotting with the secondary
antibody.
Quantitative Real time PCR (qRT-PCR). Total RNA was extracted by using
TRI-reagent (Sigma, PT). cDNA was generated using NZY First-Strand cDNA
Synthesis Kit (NZYTech, PT). Real Time PCR was performed on a BioRad CFX96
quantitative real time PCR machine using the SYBR Green JumpStart master
mix (Sigma, PT). The primer sequences (NZYTech, PT) for measuring p16, p27,
FasLG, Bim, TRAIL, p21, Bax, PUMA, MDM2, TRIB1, TRIB2, TRIB3 and GAPDH
are shown in Supplementary Table 3. Data analysis was carried out using the
2DDCT method24.
Flow cytometric cell cycle analysis. Cells were grown to 70% conﬂuence. Cells
were mock treated/exposed to each compound for the time points indicated.
Samples were collected, washed (PBS) and ﬁxed (70% ethanol). Ethanol was
removed and samples were resuspended in PBS. Propidium iodide (2.5mgml) was
added to each sample. Samples were run on a Fluorescence Activated Cell Scanner
(FACS) and the percentage populations (sub-G1, G1, S and G2 phases) determined.
50,000 total events were scored per study Data was analysed using Inﬁnicyt
(Cytognos).
In vivo studies. In vivo efﬁcacy studies were performed using 293T-GFP and
293T-TRIB2 cells injected subcutaneously in the ﬂank of female NOD/SCID mice.
Animals were treated with either vehicle alone (20% N-Methyl-2-pyrrolidone
(NMP) 80% polyethylene glycol (PEG) 300) or BEZ235 (30mg kg 1 by oral
gavage. Treatment was administered daily for the indicated length of time.
Tumours were measured manually by calliper daily. All in vivo modelling
was carried out according to guidelines, regulations set out in Portuguese law
(Portaria 1005/02 and Portaria 1131/97), which transcribes the European Guideline
86/609/EC and approved by the CBMR Biote´rio ethics board.
Figure 4 | TRIB2-conferred resistance to PI3K inhibitors in vivo and ex vivo and correlates with poor clinical prognosis. (a) Kaplan–Meier analysis of
isogenic TRIB2 cell lines grow subcutaneously in NOD/Scid mice treated with vehicle (n¼ 7), of BEZ235 (n¼ 7). The presence of TRIB2 signiﬁcantly
reduced survival (log rank P¼0.033) when treated daily with BEZ235. (b) TRIB2 overexpressing 293T tumours (n¼ 7) show little to no response to daily
administration of BEZ235 compared to isogenic lines with endogenous (low, n¼ 7) TRIB2 expression. (c) Representative immunoblot analysis of key
proteins of interest from in vivo treated tumours. Only three tumours were present from the 293T-empty-BEZ235 treatment group. Red line (on 293-TRIB2
treated immunoblots highlight bands from the same membrane that were spliced due to lane gaps left on the original full immunoblot. Original full
membranes are provided in Supplementary Information; Supplementary Fig. 19). (d) (left panel) Quantitative real time PCR (qRT-PCR) analysis of gene
expression in ex vivo metastatic melanoma samples (n¼ 20) versus normal control tissue (n¼ 10). Data were analysed by two-way ANOVA) and values
represent the mean±s.d. (right panel), Quantitative real time PCR (qRT-PCR) analysis of gene expression in ex vivometastatic melanoma samples (n¼ 20)
versus normal control tissue (n¼ 10) classiﬁed by clinical response to ﬁrst line chemotherapy (complete response n¼ 5, stable disease n¼ 5 or progressive
disease n¼ 10). Data were analysed by two-way ANOVA) *Pr0.05, **Pr0.01, ***Pr0.001) and values represent the mean±s.d. (e) Representative
immunoblot analysis of the AKT signalling cascade from ex vivo metastatic melanoma samples compared to normal tissue samples. (f) Representative
immunoﬂuorecent images of metastatic melanoma dual stained for TRIB2 and pSer473-AKT1 demonstrating co-staining and interaction. (g) Kaplan–Meier
analysis from melanoma patients in the GSE65904 dataset classiﬁed based on low (Z1.5 fold) or high (Z2.5 fold) TRIB2 expression. Log-rank tests reveal
that TRIB2 expression is highly signiﬁcant for patient prognosis with median survival for low (4,450 days) and high (394 days) expression respectively.
(h) Kaplan–Meier analysis for metastasis-free survival based on low (Z1.5 fold) or high (Z2.5 fold) TRIB2 expression (i) Proposed model of TRIB2-
mediated drug resistance.
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Fixing and staining samples for immunoﬂuorescence. To ﬁx samples/cells,
slides/coverslips were ﬁxed and permeabilised for 15min in dry methanol at
 20 C and rehydrated in PBS. Samples/cells were blocked (donkey serum 1:30)
for 1 h at 37 C in a humiﬁed chamber incubated with primary antibody
(either Anti-pSer473AKT1 or TRIB2) for 1 h at 37 C in a humiﬁed chamber
followed by PBS washing and incubation with a ﬂuorescent secondary antibody
(Molecular Probes A21207 or A11055) for 1 h at 37 C in a humiﬁed chamber.
Antibody solutions were made in PBS (Sigma). Following labelling procedures,
samples/cells were mounted on glass slides in Clear Mount mounting solution
(Invitrogen).
Statistical analysis. Statistical signiﬁcance was assessed by two-way analysis of
variance (ANOVA) or the two-tailed Students t-test. Statistical signiﬁcance was
deﬁned as PZ0.05. Results are expressed as the mean±s.d. or s. e. of the mean
(s.e.m.) and are described in each ﬁgure legend when applied.
Data availability. The authors declare that the data supporting the ﬁndings of this
study are available within the paper and its Supplementary Information ﬁles.
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